Effect of porcine somatotropin administration in young pigs during the growth phase from 10 to 25 kilograms.
We conducted two experiments to determine the efficacy of exogenous porcine somatotropin (pST) on enhancing performance during an early phase of growth (10 kg initial BW) when pigs are already growing efficiently and have high rates of lean deposition and low rates of lipid deposition. In Exp. 1, performance was measured on 45 barrows that received one of five daily doses (0, 50, 100, 150 and 200 microg/kg BW) of recombinant pST. In Exp. 2, 27 barrows were used in a slaughter-balance study in which two groups received daily either buffer (control) or 120 microg/kg BW of pST and the third group was slaughtered for initial body composition. In both experiments, pigs received daily i.m. injections of their respective dose for 20 d. The diet was fed for ad libitum consumption and calculated to contain 3.5 Mcal DE/kg, 22.3% CP, and 1.5% lysine. Administration of pST failed to alter overall growth rate or efficiency of gain in either experiment. However, in Exp. 2 pigs treated with pST had increased deposition rates of protein and water but reduced lipid deposition rates. Furthermore, pST treatment resulted in characteristic reductions in plasma urea nitrogen and elevations in glucose and NEFA. Plasma concentrations of insulin and IGF-I were also increased, but pST reduced IGF-II and IGF binding protein-2. Overall, the data demonstrated that very young pigs respond to pST with enhanced lean tissue accretion and metabolic changes, but the response is attenuated compared with previous studies in older growing pigs.
Harrell
R J
RJ
Department of Animal Science, Cornell University, Ithaca, NY 14853, USA.
Thomas
M J
MJ
Boyd
R D
RD
Czerwinski
S M
SM
Steele
N C
NC
Bauman
D E
DE
D000818:Animals; D001786:Blood Glucose / Q000032:analysis / Q000378:metabolism; D001806:Blood Urea Nitrogen; D001823:Body Composition / Q000187:drug effects / Q000502:physiology; D004032:Diet / Q000662:veterinary; D004305:Dose-Response Relationship, Drug; D005230:Fatty Acids, Nonesterified / Q000097:blood; D013006:Growth Hormone / Q000008:administration & dosage / Q000494:pharmacology*; D007273:Injections, Intramuscular / Q000662:veterinary; D007328:Insulin / Q000097:blood; D018969:Insulin-Like Growth Factor Binding Proteins / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000032:analysis / Q000378:metabolism; D007335:Insulin-Like Growth Factor II / Q000032:analysis / Q000378:metabolism; D008297:Male; D011897:Random Allocation; D013552:Swine / Q000097:blood / Q000254:growth & development* / Q000502:physiology*; D015430:Weight Gain / Q000187:drug effects* / Q000502:physiology
D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D007328:Insulin; D018969:Insulin-Like Growth Factor Binding Proteins; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; D013006:Growth Hormone